COVID-19 Coding Resources

COVID-19 Vaccine Codes  |  AAP Resources  |  News

Updated 9/1/2022

COVID-19 Vaccine Codes

The CPT Editorial Panel has developed SARS-CoV-2 vaccine product and immunization administration codes. Download the AAP COVID-19 Vaccine Coding Chart for complete details. 

Updated 10/24/2022

AAP Resources

The AAP is here to support you as you implement new policies and practices related to COVID-19. Because this is a fluid situation, we encourage you to refer regularly to the dedicated AAP COVID-19 coding resource. 

The following Pediatric Coding Newsletter articles address COVID-19 as well: 

• AAP COVID-19 Coding Resources 
• Coding Compliance and the Public Health Emergency
• Coding for Administration of a COVID-19 Vaccine
• COVID-19 Coding Update 
• CPT: Quantitative SARS-CoV-2 Test and Public Health Emergency Practice Expense 
• Did COVID-19 Reveal Your Practice Needs a Checkup?
• Is Your Practice's Financial Health Recovering from COVID-19?
• New ICD-10-CM Guidelines: COVID-19 Related Services 
• Reporting Encounters for Immunization Safety Counseling
• Update: Coding and COVID-19 

Other resources available from the AAP include

New CPT Codes Released Ahead of FDA Approval

Updated 2/4/2022

The AMA has announced an update to the CPT code set for new product and administration codes assigned to the Pfizer-BioNTech COVID-19 vaccine for children 6 months of age to 5 years of age. Please note that the product has not yet received FDA approval. 

Product Code
91308 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

Administration Codes
0081A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose

0082A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose

CPT Releases New Code for J&J's Janssen Vaccine

Updated 10/29/2021

On October 29, a new code was released for the administration of the booster dose of the Janssen vaccine. The new code is 0034A. The product code (91303) remains the same. 

COVID-19: Vaccine and Administration Codes for Ages 5 Through ­11 Years

Updated 10/13/2021

The American Medical Association released the following codes on October 6, 2021, in anticipation of emergency use authorization of the Pfizer SARS-CoV-2 vaccine in patients aged 5 through 11 years old. Code 91307 is reported for the vaccine product authorized for use in children aged 5 through 11 years.

#~l91307        Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

Please note that administration of the vaccine product is not reported with immunization administration codes 90460–90461. Instead, report administration code 0071A (first dose) or 0072A (second dose) for administration of the vaccine represented by code 91307. (Each SARS-CoV-2 vaccine product code is paired with unique administration codes that are used only for administration of that individual product.)  Do not report 91307 in conjunction with any other vaccine administration code.

#l0071A            Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose

#l0072A                          second dose

Click here for more details on these codes and information about codes reported for other immunization against or services provided for diagnosis or management/treatment of COVID-19. You can also download a chart of all available pediatric COVID-19 vaccine codes here.

Updated 9/23/2021

New ICD-10 Codes Related to COVID-19 Released

As a result of the ongoing public health emergency, International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) broke from its regular release schedule to release 6 new codes related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/coronavirus disease 2019 (COVID-19). The following codes go into effect on January 1, 2021: 

• Contact with and (suspected) exposure to COVID-19 (Z20.822)
• Encounter for screening for COVID-19 (Z11.52)
• Personal history of COVID-19 (Z86.16) 
• Multisystem inflammatory syndrome (MIS) (M35.81) 
• Other specified systemic involvement of connective tissue (M35.89)
• Pneumonia due to COVID-19 (J12.82)

For more details on how to report these codes, please refer toCoding During the COVID-19 Public Health Emergency. The official ICD-10-CM release can be found at https://www.cdc.gov/nchs/data/icd/Announcement-New-ICD-code-for-coronavirus-19-508.pdf.